Difficulty: Medium
Average Score: 90%
Practice
A 33-year-old pregnant woman begins taking a new drug, Drug X, for morning sickness. Drug X has been found to have adverse fetal effects in animal models, but no adequate human studies have been done. Under which FDA pregnancy category would Drug X fall?
Correct answer
C
Rationale
In the context of the FDA pregnancy categories, Drug X would fall under Category C. Category C includes drugs for which animal reproduction studies have shown an adverse effect on the fetus, but there are no adequate and well-controlled studies in humans.
The correct answer is Category C because Drug X has demonstrated adverse fetal effects in animal models. This indicates a potential risk to the fetus, but without sufficient human data, the extent of this risk in pregnant women is uncertain. Therefore, caution is warranted when considering its use during pregnancy.
Option A (Category A) would imply that adequate and well-controlled studies in pregnant women have not shown any risk to the fetus, which is not the case for Drug X based on animal studies. Option B (Category B) would indicate no evidence of risk in animal studies, which is also not applicable here. Option D (Category D) would suggest positive evidence of fetal risk in humans, which has not been established for Drug X.
From an educational standpoint, understanding FDA pregnancy categories is crucial for healthcare professionals to make informed decisions regarding medication use in pregnant women. It emphasizes the importance of weighing the potential risks and benefits of drug therapy during pregnancy, especially when human data is lacking. This knowledge ensures safe and evidence-based care for pregnant patients.
The correct answer is Category C because Drug X has demonstrated adverse fetal effects in animal models. This indicates a potential risk to the fetus, but without sufficient human data, the extent of this risk in pregnant women is uncertain. Therefore, caution is warranted when considering its use during pregnancy.
Option A (Category A) would imply that adequate and well-controlled studies in pregnant women have not shown any risk to the fetus, which is not the case for Drug X based on animal studies. Option B (Category B) would indicate no evidence of risk in animal studies, which is also not applicable here. Option D (Category D) would suggest positive evidence of fetal risk in humans, which has not been established for Drug X.
From an educational standpoint, understanding FDA pregnancy categories is crucial for healthcare professionals to make informed decisions regarding medication use in pregnant women. It emphasizes the importance of weighing the potential risks and benefits of drug therapy during pregnancy, especially when human data is lacking. This knowledge ensures safe and evidence-based care for pregnant patients.